Ministry of Health Mandates Pharmaceutical Sector Re-Registration From July 1: Three Digital Platforms, Six Days to Comply

Health Cabinet Secretary Aden Duale has directed the entire Kenyan pharmaceutical supply chain , pharmacies, chemists, manufacturers, importers, distributors, wholesalers, and healthcare facilities to register and maintain active compliance with three new national digital platforms from July 1, 2026. The platforms are the National Track and Trace System, Practice360, and Facility360, covering product serialisation, professional licensing, and facility oversight respectively. Compliance with GS1 Global Standards for product identification and traceability is also mandatory. The directive is grounded in the Digital Health Act 2023, the Health Act, and the Pharmacy and Poisons Act. With an effective date six days away, organisations that have not begun platform registration are already behind, and the compliance implications for every actor in Kenya's pharmaceutical supply chain are immediate.

Speaking at the 46th Annual Pharmaceutical Society of Kenya Conference in Mombasa, CS Duale announced that the Ministry of Health will from July 1, 2026 require all pharmaceutical sector participants to register on three national digital platforms as a condition of continued lawful operation. The scope is comprehensive: it covers the full supply chain from manufacturing and importation through distribution, wholesale, retail dispensing, and healthcare facility administration. The directive is framed as a governance reform to combat counterfeit medicines, strengthen regulatory oversight, and digitise pharmaceutical sector management. The practical reality for affected organisations is that registration, integration, and active compliance are conditions of operation, not aspirational targets.

Kenya's pharmaceutical sector is regulated primarily under the Pharmacy and Poisons Act, Cap. 244, which establishes the Pharmacy and Poisons Board as the principal regulatory authority for pharmaceutical products and professionals. The Board oversees licensing of manufacturers, importers, distributors, pharmacies, and pharmaceutical professionals. The Health Act 2017 provides the broader public health governance framework within which the sector operates. The Digital Health Act 2023 is the legislative basis for the mandatory digital platform requirements now being activated, having established the framework for national health information systems, digital health records, and mandatory participation by health sector actors in government-designated digital infrastructure. The GS1 Global Standards requirement covering product identification, serialisation, authentication, and traceability aligns Kenya's pharmaceutical traceability framework with international standards used across regulated pharmaceutical markets globally, including those required by the World Health Organization's prequalification framework.

The July 1 effective date is the sharpest compliance pressure point in this directive. The National Track and Trace System requires end-to-end product monitoring from importation and manufacturing through to dispensing and consumption . This is not a simple registration form but a technology integration exercise requiring system connectivity, staff training, and data infrastructure. Practice360 and Facility360 require professional and facility licensing to migrate onto new digital platforms. Organisations that have not begun this process face the prospect of operating in regulatory breach from day one. The Pharmacy and Poisons Board's enforcement posture in the opening weeks of July will determine how the sector interprets the real compliance deadline, but legal exposure exists from July 1 regardless of enforcement timing.

The GS1 serialisation requirement carries a separate operational burden. Manufacturers and importers must ensure that every product unit is serialised and traceable under GS1 standards before it enters the supply chain. For importers sourcing from manufacturers that do not already use GS1 standards, this creates an immediate procurement and supply chain compliance challenge. Distributors and wholesalers that receive non-serialised stock after July 1 face a question about whether handling that stock constitutes a breach of the new requirements. These operational gaps are not addressed in the directive as reported, and the Pharmacy and Poisons Board needs to issue guidance on transitional arrangements urgently.

The counterfeit medicine dimension gives this directive strategic weight beyond administrative compliance. Kenya has a documented problem with substandard and counterfeit pharmaceutical products entering its supply chain, a risk that the NTTS is specifically designed to address. For healthcare facilities and pharmacies, the track and trace requirement creates an accountability chain that makes it significantly harder to handle diverted or counterfeit stock without detection. That accountability cuts both ways: facilities that inadvertently dispense substandard products captured by the system will face regulatory scrutiny they could previously have avoided.

The Ministry of Health's pharmaceutical re-registration directive is operationally urgent and legally enforceable from July 1. The technology integration requirements are substantive, the effective date is days away, and the Pharmacy and Poisons Board has not yet published the transitional guidance the sector needs. Organisations that treat this as an administrative formality will find the compliance consequences are not.